Barbituates and biliary function.
This paper reviews the principal effects of phenobarbital on biliary function. Phenobarbital administration is followed by an increase in bile flow. This is mainly due to an increase in the bile salt-independent fraction of canalicular bile flow possibly through an increase in canilicular Na+-K+ ATPase activity. In addition, bile salt excretion may be increased. This effect of barbiturates on choleresis appears to be independent of microsomal enzyme induction. Barbiturates increase the uptake, storage and excretion of various dyes, for example sulfobromophthalein. Phenobarbital increases bilirubin clearance by the liver; it enhances bilirubin-UDP-glucuronyl transferase activity; whether the influence on bilirubin clearance is related to the effect on the enzyme is unknown. The influence of phenobarbital on biliary lipids is markedly different from one species to the other. In the rhesus monkey and in the rat, the relative concentration of cholesterol is decreased; in the hamster it is increased, and in man it appears largely unaffected. These effects of phenobarbital have been utilized in the treatment of chronic unconjugated hyperbilirubinemia and of certain cholestatic syndromes. Phenobarbital alone has been useful, so far, in the treatment of cholesterol gallstones.
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D001646:Bile / Q000187:drug effects / Q000378:metabolism; D001647:Bile Acids and Salts / Q000378:metabolism; D001659:Biliary Tract / Q000187:drug effects*; D001663:Bilirubin / Q000378:metabolism; D002769:Cholelithiasis / Q000188:drug therapy; D002779:Cholestasis / Q000188:drug therapy; D002784:Cholesterol / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System; D003864:Depression, Chemical; D000882:Haplorhini; D006801:Humans; D006932:Hyperbilirubinemia / Q000188:drug therapy; D007231:Infant, Newborn; D007566:Jaundice, Chronic Idiopathic / Q000188:drug therapy; D008099:Liver / Q000378:metabolism; D008253:Macaca mulatta; D010634:Phenobarbital / Q000494:pharmacology* / Q000627:therapeutic use; D010743:Phospholipids / Q000378:metabolism; D051381:Rats; D012636:Secretory Rate / Q000187:drug effects; D013268:Stimulation, Chemical; D013448:Sulfobromophthalein
D001647:Bile Acids and Salts; D010743:Phospholipids; D013448:Sulfobromophthalein; D003577:Cytochrome P-450 Enzyme System; D002784:Cholesterol; D000251:Adenosine Triphosphatases; D001663:Bilirubin; D010634:Phenobarbital